Your Global Leader in Stem Cell Market Research
COLUMBIA, Md., Sept. 29, 2025 — TEDCO, Maryland’s economic engine for technology companies, announces the attendance of Maryland Governor Wes Moore at the upcoming 2025 Entrepreneur Expo. The premier event will take place at The Hotel at the University of Maryland on October 21, 2025. Gov. Moore will be making a special appearance during the lunch keynote session. [Read more…]
SHENZHEN, China, Sept. 16, 2025 — Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (DMF) registration with the U.S. FDA.
Exosomes, as a next-generation bioactive carrier, boast unique advantages such as low immunogenicity, strong tissue penetration, and potential for targeted modification, offering immense promise for medical applications. However, the technical barriers and research challenges in Exosome development place them at the forefront of complexity among bioactive material fields. [Read more…]
September 24, 2025 – Takara Bio Europe announces the launch of Cellartis® MSC EV Wonder™, a defined, xeno-free medium engineered for the scalable production of extracellular vesicles (EVs) from human mesenchymal stem cells (MSCs).
MSC-derived EVs are increasingly recognized as next-generation, cell-free therapeutic candidates, offering regenerative and immunomodulatory benefits without the safety concerns associated with administering intact MSCs. As the field shifts from MSC-based approaches to MSC-EVs, researchers are seeking solutions that deliver both robust yields and reproducible quality at scale. [Read more…]
LEIDEN, Netherlands — Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment, today announced the launch of Ncyte® NHP-C vCardiomyocytes, the first commercially available ventricular-like cardiomyocytes derived from induced pluripotent stem cells (iPSCs) of cynomolgus monkeys. New Ncyte® NHP-C vCardiomyocytes provide a scalable, ethical and translational tool for cross-species cardiac studies. [Read more…]
Rochester, NY, September 24, 2025 – After two decades of pioneering hematology and cancer stem cell research, Sanatela AT Medical Solutions Inc. proudly announces that the United States Patent and Trademark Office (USPTO) has officially issued its long-awaited patent for a revolutionary cancer detection and treatment platform. [Read more…]
